Abstract | AIMS: In a short-term study including 31 patients with type 2 diabetes, glucagon-like peptide 1 receptor agonist (GLP-1 RA) treatment was associated with a significant reversible decline in GFR. Twenty-three patients re-initiated GLP-1 RA treatment after the primary study, and the aim was to investigate the long-term effect on kidney function. METHODS: We included 30 patients in a one-year extension study, all initially treated with liraglutide for seven weeks. During follow-up 23 were treated with liraglutide and seven untreated. Primary outcome was change in GFR ((51)Cr- EDTA plasma clearance). RESULTS: Patients were 61.5 (10.0) years and HbA(1c) 60.1 (13.8) mmol/mol. Baseline GFR was 100.6 (24.9) mL/min/1.73 m(2) and was reduced by 11 (95% CI: 6.6-15.7, p < 0.001) mL/min/1.73 m(2), independent of change in 24-h systolic blood pressure (SBP), weight, UAER or HbA(1c) (p≥0.33). Geometric mean (IQR) of UAER was 25.5 (9.9-50.9) mg/d and was reduced by 27 (95% CI: 5-44; p = 0.020)%, and 24-h SBP was reduced by 8.2 (p = 0.048) mmHg. No changes occurred in untreated patients. CONCLUSIONS: Long-term treatment with liraglutide was associated with a reduction in measured GFR similar to the effect during short-term treatment, suggesting a metabolic or haemodynamic reversible effect and not structural changes. Moreover, UAER and 24-h SBP were reduced. TRIAL REGISTRATION: ClinicalTrials.gov identifier: NCT01499108.
|
Authors | Bernt Johan von Scholten, Tine Willum Hansen, Jens Peter Goetze, Frederik Persson, Peter Rossing |
Journal | Journal of diabetes and its complications
(J Diabetes Complications)
Vol. 29
Issue 5
Pg. 670-4
(Jul 2015)
ISSN: 1873-460X [Electronic] United States |
PMID | 25935863
(Publication Type: Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright © 2015 Elsevier Inc. All rights reserved. |
Chemical References |
- GLP1R protein, human
- Glucagon-Like Peptide-1 Receptor
- Glycated Hemoglobin A
- Hypoglycemic Agents
- hemoglobin A1c protein, human
- Liraglutide
|
Topics |
- Aged
- Albuminuria
(etiology)
- Diabetes Mellitus, Type 2
(complications, drug therapy, metabolism, physiopathology)
- Diabetic Nephropathies
(physiopathology, prevention & control)
- Female
- Follow-Up Studies
- Glomerular Filtration Rate
(drug effects)
- Glucagon-Like Peptide-1 Receptor
(agonists, metabolism)
- Glycated Hemoglobin
(analysis)
- Humans
- Hyperglycemia
(prevention & control)
- Hypoglycemic Agents
(therapeutic use)
- Kidney
(drug effects, physiopathology)
- Liraglutide
(therapeutic use)
- Male
- Middle Aged
- Renal Insufficiency
(physiopathology, prevention & control)
|